Web table 1: Reporting of CONSORT for Abstracts items across journals in 2006

	Total (n=245)
'Randomized' in the title	176 (72%)
Trial design described (e.g., parallel, cluster, cross-over),	50 (20%)
Participant eligibility described	202 (82%)
Setting described	139 (57%)
Interventions for each group described	176 (72%)
Specific objective described	233 (95%)
Primary outcome defined	156 (64%)
Sequence generation described	0 (0%)
Allocation concealment described	0 (0%)
Blinding described (detailed)* Blinding described (generic)†	14 (6%) 117 (48%)
Number participants randomized to each group described	105 (43%)
Number of participants analysed in each group described	48 (19%)
Primary outcome, result for each group and effect size described	105 (43%)
Precision (e.g. CI) described	156 (64%)
Harms described	86 (35%)
Conclusions described	243 (99%)
Trial registry given	186 (76%)
Funding source described	0 (0%)

* Abstract detailed specifically who was blinded (e.g. whether or not participants, care providers, and those assessing outcomes were blinded to group assignment).
† Abstract simply mention the word single, double blind, placebo without further description. 14 abstracts were reported as unblinded / open label.